Recent 8-K filings for CAI

• September 14, 2026, 4:38 PM ET other materiality 0.00 neutral item 7.01

  Caris Life Sciences discloses investor presentation for Morgan Stanley healthcare conference

  Announces use of investor presentation at Morgan Stanley 24th Annual Global Healthcare Conference on Sept 14, 2026.

• August 5, 2026, 4:12 PM ET earnings materiality 0.85 positive item 2.02item 9.01

  Caris Life Sciences Q2 revenue up 45% to $263.7M; raises FY 2026 guidance to $1.03-1.04B

  Revenue $263.7M (+45% YoY); net loss narrowed to $0.6M from $71.8M loss; positive Adj. EBITDA $55.7M.

• June 5, 2026, 5:03 PM ET other material materiality 0.15 neutral item 5.07 ◈ Shareholder Votes ×2

  Caris Life Sciences shareholders elect ten directors, ratify Deloitte as auditor for FY2026

  Annual Meeting held June 4, 2026; 273.7M shares represented (96.8% of 282.7M outstanding).

• May 7, 2026, 7:59 PM ET earnings materiality 0.75 positive item 2.02item 9.01 ◈ Earnings Releases

  Caris Life Sciences Q1 revenue up 79% to $216.2M, net loss narrows to $0.5M

  Revenue $216.2M (+79% YoY); gross margin 65% vs 47% a year ago.

• April 2, 2026, 7:59 PM ET debt materiality 0.50 neutral item 1.01item 1.02item 2.03 ◈ Material Agreements ×2◈ Debt Financings

  Caris Life Sciences enters $400M term loan and $300M delayed draw facility with Blue Owl and Blackstone

  Borrowed $400M initial term loan to repay existing credit agreement from January 2023.

• February 26, 2026, 6:59 PM ET earnings materiality 0.85 positive item 2.02item 7.01item 9.01

  Caris Q4 net income $82M; FY25 rev $812M (+97%); guides FY26 rev $1.0-1.02B

  Q4 2025 revenue $292.9M (+125% YoY); net income $82.0M vs loss of $36.9M prior year.

• January 12, 2026, 6:59 PM ET earnings materiality 0.85 positive item 2.02item 7.01item 9.01

  Caris Life Sciences reports preliminary Q4 2025 revenue of ~$281M, up 116% YoY; FY revenue ~$800M, up 94%

  Q4 revenue ~$281M (+116% YoY); Molecular Profiling services ~$270M including ~$81M prior-period true-ups.

• November 5, 2025, 6:59 PM ET earnings materiality 0.85 positive item 2.02item 9.01

  Caris Life Sciences Q3 revenue $216.8M, up 113%, raises FY2025 guidance to $720-730M

  Net income of $24.3M vs. loss of $67.7M YoY; diluted EPS $0.08 vs. ($2.59).

• October 30, 2025, 7:59 PM ET other material materiality 0.35 neutral item 3.03item 5.03item 9.01 ◈ Governance Changes

  Caris Life Sciences adopts 3% ownership threshold for derivative proceedings

  Board approved amendment to bylaws on October 30, 2025 requiring 3% beneficial ownership to institute or maintain a derivative proceeding.

• August 12, 2025, 7:59 PM ET earnings materiality 0.75 positive item 2.02item 9.01

  Caris Life Sciences Q2 2025 revenue $181.4M (+81% YoY); Adj. EBITDA positive $16.7M; FY rev guidance $675-685M

  Total revenue $181.4M, up 81.3% YoY; gross margin 62.7% vs 37.5% a year ago.

• June 20, 2025, 7:59 PM ET other material materiality 0.85 positive item 5.03item 8.01item 9.01 ◈ Governance Changes ×2

  Caris Life Sciences completes IPO of 23.5M shares at $21.00, raising $494.1M gross

  IPO of 23,529,412 shares of common stock at $21.00 per share closed June 20, 2025.

Earnings & guidance

Materiality & sentiment trend

Max materiality 0.85 · Median 0.75 · Most common event earnings

7 positive 0 negative 4 neutral

source · CAI on sec.gov